14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DRAM vs IREN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
IREN Overall Winner
6-Pillar Tally: DRAM 2 – 3 IREN (1 Tie)
Matrix Metrics: DRAM 3 – 7 IREN
As of Nov 16, 2026, IREN Limited (IREN) is the stronger overall head-to-head candidate over DRAM (DRAM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DRAM carries a Unified Composite Score of 49.1/100 (HOLD) at $39.27 (N/M Forward P/E, N/A operating margin), whereas IREN carries 48.2/100 (HOLD) at $16.39 (65.4x Forward P/E, -72.9% operating margin).
Composite vs. Pillar Nuance: While DRAM currently prints a higher short-term Unified Composite Score (49.1/100 HOLD vs. IREN 48.2/100 HOLD), IREN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-72.9% vs. N/A operating margin) and revenue trajectory (-5.0% vs. N/A YoY).
Technical & Structure Timing Caution: DRAM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.7); meanwhile IREN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DRAM vs IREN. Trailing 12-month operating profitability (DRAM N/A vs IREN -72.9%) and valuation multiples (DRAM N/M vs IREN 65.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Capital Markets value chain with $7.7B market capitalization and -72.9% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ DRAM vs IREN Key Questions & Quantitative Answers
As of Nov 16, 2026, IREN Limited (IREN) is the stronger overall head-to-head candidate over DRAM (DRAM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DRAM carries a Unified Composite Score of 49.1/100 (HOLD) at $39.27 (N/M Forward P/E, N/A operating margin), whereas IREN carries 48.2/100 (HOLD) at $16.39 (65.4x Forward P/E, -72.9% operating margin). Composite vs. Pillar Nuance: While DRAM currently prints a higher short-term Unified Composite Score (49.1/100 HOLD vs. IREN 48.2/100 HOLD), IREN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-72.9% vs. N/A operating margin) and revenue trajectory (-5.0% vs. N/A YoY). Technical & Structure Timing Caution: DRAM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.7); meanwhile IREN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IREN leads the Growth & Scale pillar: DRAM posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with IREN at -5.0% YoY revenue growth and +42.9% YoY earnings growth on $695M TTM revenue (73.4% gross margin, -72.9% operating margin). On trailing 12-month operating scale, DRAM generates N/A in USD-normalized revenue versus $695M for IREN. In operating R&D and SG&A reinvestment, DRAM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IREN.
IREN screens cheaper on headline valuation multiples. DRAM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas IREN trades at 65.4x Forward P/E, 65.4x Trailing P/E, 4.05x PEG, and 20.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DRAM (N/A ROE) versus IREN (-33.8% ROE) capital efficiency.
In options market volatility and institutional positioning, DRAM carries 86.4% implied volatility (74th %ile, Elevated (60th–80th %ile)), a 0.83x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (4.02β · 102% Vol realized risk). By comparison, IREN carries 129.7% implied volatility (32nd %ile, Balanced (25th–60th %ile)), a 2.67x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.86β · 139% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.